A vaccine is the world’s best hope to end AIDS.

Despite impressive progress in delivering HIV treatment, ending the AIDS pandemic will require new approaches to prevent HIV infection. An effective vaccine would dramatically reduce HIV infections and deaths globally. Without a vaccine, we may actually see increases in infection rates.

IAVI’s Vision: A World Without AIDS
Vaccines work. We need one for AIDS.

The global fight to end AIDS will not succeed without continued investment in HIV vaccine research.

Today, only half of HIV-infected individuals receive antiretroviral drugs. While global antiretroviral programs have prolonged the lives of millions and reduced AIDS deaths, infection rates are still unacceptably high. Vaccines are far less expensive to administer than daily, lifelong drug treatments. They provide long-lasting benefit.

The International AIDS Vaccine Initiative (IAVI) is dedicated to accelerating development of vaccines to prevent AIDS.

By focusing on the populations most at risk of HIV infection, IAVI works with its global partners to accelerate discovery research, translate discoveries into new products, test candidate vaccines, and ensure global access to a future vaccine.
**Discovery**
IAVI’s research has expanded understanding of how “broadly neutralizing antibodies” can block HIV infection, and how to elicit these protective antibodies with a vaccine.

**Translation**
IAVI’s Vaccine Product Development Center has accelerated over two dozen vaccine candidates – developed by IAVI and its global partners – into clinical trials.

**Clinical Network**
Our 15-year partnership with USAID established a network of 11 clinical research centers in Africa and India that builds sustainable HIV research capacity and empowers their scientists.

IAVI’s work
IAVI translates breakthrough research into promising vaccine candidates. IAVI works to:

**Discover** new approaches to developing vaccines and other means of preventing HIV.

**Accelerate** discovery, translational and clinical research through laboratories in the U.S., India, Africa, and the U.K.

**Strengthen** in-country vaccine research capacity through a unique network of clinical research partners in Africa. This network has helped empower an outstanding cadre of African scientists now working to support their nations’ AIDS responses.

**Partner** with leading scientists in academia, government, and industry in the U.S. and Europe. IAVI applies the latest biopharmaceutical industry product development expertise to develop innovative products tailored to the needs of at-risk populations.

**Share** IAVI’s resources with other innovators to help the HIV community as a whole succeed.

**Extend** IAVI’s core capabilities in HIV disease prevention to solving other global health challenges.

“IAVI is small, entrepreneurial, and focused... We’re proud to be supporting the pioneering work of IAVI and urge you to join us in the development of an AIDS vaccine.”

Bill & Melinda Gates Foundation